The Biggest CBD Anxiety Trial in Years

178 people, fifteen weeks and a placebo group produced a clear result, and a dose that changes how to read it

Most of the research behind CBD and anxiety is small. Twenty people, forty people, a single session in a laboratory, a stress task, a measurement, and a paper.

That work has been genuinely useful, but it leaves the important question open. A single dose before a stressful task tells you something about that moment. It tells you very little about taking CBD for months.

A trial published in the Asian Journal of Psychiatry in 2024 set out to answer the longer question, and it is one of the more substantial pieces of work in this area.

Why the Design Matters

The details here are worth walking through because they are what separate this from most of what gets written about CBD and anxiety.

• Randomized, so participants were assigned to CBD or placebo by chance rather than choice
• Double-blind, so neither the participants nor the assessing clinicians knew who was on what
• Placebo-controlled with a parallel group design, meaning a real comparison group ran alongside for the whole study
• Multicentre, across several sites in India, rather than one clinic with one team’s habits
• Fifteen weeks, not a single afternoon
• 178 participants, randomized 89 to CBD and 89 to placebo

The participants were medication-free adults with mild to moderate nonspecific anxiety. These were not people with severe diagnosed disorders on other medication, which makes the group closer to the general population than most clinical trials manage.

What the Study Found

Anxiety was measured with two standard instruments. On both, a bigger drop is better.

• On the GAD-7, the difference between CBD and placebo from baseline to end of treatment was −7.02 (p less than 0.0001)
• On the HAM-A, the difference was −11.9 (p less than 0.0001)

Those p-values describe a result very unlikely to be chance.

Secondary measures moved too. The researchers reported that clinical global impression scores, depression scores on the PHQ-9, and sleep quality on the PSQI all met their endpoints, which suggests the effect was not confined to the anxiety questionnaires alone.

On safety, the trial reported no serious adverse events, and described the formulation as well tolerated across the fifteen weeks.

An Important Consideration That Should Be Noted

Here is a detail that changes how this study should be read, and it is the one most likely to be left out of a summary.

The trial used 300 to 600 mg of CBD per day.

That is not a consumer dose. It is not close to a consumer dose. Most people taking CBD from a shop-bought tincture or gummy are somewhere between 10 and 70 mg a day, which means this trial used somewhere between five and sixty times what is in ordinary use.

There is a second complication. The product was a nanodispersible oral solution, a pharmaceutical formulation in which CBD is encapsulated so that more of it survives digestion and reaches circulation. That is a deliberate engineering choice to solve CBD’s absorption problem. See another study: You May Be Wasting Most of Your CBD

So the reading is narrower than the headline. This trial demonstrates that a specific pharmaceutical CBD preparation, at prescription-scale doses, over fifteen weeks, beat placebo on anxiety by a wide margin. It does not demonstrate that a 25 mg gummy will do the same thing, and it would be misleading to present it as though it did.

That is worth knowing before anyone reads a headline about this study and draws the wrong conclusion from it.

What Supporting Studies Add

Two other pieces of research help place this one, and they pull in slightly different directions.

Bergamaschi and colleagues, Neuropsychopharmacology, 2011. A randomized, double-blind, placebo-controlled study in treatment-naïve social anxiety patients found that CBD reduced anxiety induced by a simulated public speaking test. The dose was 600 mg, at the top of the range used in the newer trial. This is one of the most-cited pieces of evidence in the field, and it points the same way.

Shannon and colleagues, The Permanente Journal, 2019. A large case series of adults in a psychiatric clinic, most taking around 25 mg of CBD daily. Anxiety scores decreased in the majority within the first month and largely stayed down. The dose here is squarely in consumer range, which makes it the most relatable of the three.

The catch is that a case series has no control group and no blinding. People who choose to take something and then report feeling better are not evidence of the same weight as a randomized comparison against a placebo.

Worth noting across the three: the most rigorous designs have tested the highest doses, while the study closest to a consumer dose is the one with the weakest design. That is a gap in the research rather than a finding about what lower doses do.

What the Study Didn’t Prove

It does not transfer to an ordinary bottle. Different dose, different formulation, engineered for absorption. Both differences point in the same direction, meaning a standard product at standard milligrams would deliver considerably less.

It was conducted in one country. The trial ran across several centres in India, so it was not a globally representative sample.

“Mild to moderate nonspecific anxiety” is a specific group. Medication-free adults, not people with severe or diagnosed anxiety disorders, and not people already on treatment.

Fifteen weeks is longer than most, and still not long. Anxiety is often managed over the years.

Nothing here makes CBD a treatment for anxiety. It is not approved as one, and this trial does not change that. Anyone struggling with anxiety should be talking to a clinician rather than to a shop.

What This Means for You

Dose is the whole conversation. The single most useful thing to take from this study is how much CBD it took to produce that result. When a headline says a trial found CBD effective for anxiety, the follow-up question is always how much, and the answer usually explains the gap between the research and the experience.

Formulation is the second half of it. A nanodispersible preparation exists precisely because ordinary swallowed CBD absorbs poorly. Milligrams on a label describe what went in, not what arrived.

Consistency was built into the design. This was daily dosing over fifteen weeks, with measurement at the end. Whatever effect there was accumulated. Judging any product over a few scattered days is not a fair test of it.

Sleep and mood moved alongside anxiety. The PSQI and PHQ-9 results are a reminder that these things travel together, and that improvement in one is difficult to separate cleanly from improvement in another.

---

About the Original Study

Title: Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial

Published: Asian Journal of Psychiatry, July 2024; 97:104073

Authors:

• Prasad Rao Gundugurti
• Nagaraju Banda
• Siva Sankara Rao Yadlapalli
• Arjun Narala
• Ramyasree Thatikonda
• Chandrashekhar Kocherlakota
• Kumar S. D. Kothapalli

Link: https://pubmed.ncbi.nlm.nih.gov/38797087/ (DOI: 10.1016/j.ajp.2024.104073)

---